These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 28567484)

  • 1. Measurement of liver and spleen interstitial volume in patients with systemic amyloid light-chain amyloidosis using equilibrium contrast CT.
    Yeung J; Sivarajan S; Treibel TA; Rosmini S; Fontana M; Gillmore JD; Hawkins PN; Punwani S; Moon JC; Taylor SA; Bandula S
    Abdom Radiol (NY); 2017 Nov; 42(11):2646-2651. PubMed ID: 28567484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measurement of Tissue interstitial volume in healthy patients and those with amyloidosis with equilibrium contrast-enhanced MR imaging.
    Bandula S; Banypersad SM; Sado D; Flett AS; Punwani S; Taylor SA; Hawkins PN; Moon JC
    Radiology; 2013 Sep; 268(3):858-64. PubMed ID: 23674785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tracking Multiorgan Treatment Response in Systemic AL-Amyloidosis With Cardiac Magnetic Resonance Derived Extracellular Volume Mapping.
    Ioannou A; Patel RK; Martinez-Naharro A; Razvi Y; Porcari A; Hutt DF; Bandera F; Kotecha T; Venneri L; Chacko L; Massa P; Hanger M; Knight D; Manisty C; Moon J; Quarta C; Lachmann H; Whelan C; Kellman P; Hawkins PN; Gillmore JD; Wechelakar A; Fontana M
    JACC Cardiovasc Imaging; 2023 Aug; 16(8):1038-1052. PubMed ID: 37178079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac Magnetic Resonance-Derived Extracellular Volume Mapping for the Quantification of Hepatic and Splenic Amyloid.
    Chacko L; Boldrini M; Martone R; Law S; Martinez-Naharrro A; Hutt DF; Kotecha T; Patel RK; Razvi Y; Rezk T; Cohen OC; Brown JT; Srikantharajah M; Ganesananthan S; Lane T; Lachmann HJ; Wechalekar AD; Sachchithanantham S; Mahmood S; Whelan CJ; Knight DS; Moon JC; Kellman P; Gillmore JD; Hawkins PN; Fontana M
    Circ Cardiovasc Imaging; 2021 Apr; ():CIRCIMAGING121012506. PubMed ID: 33876651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study.
    Banypersad SM; Sado DM; Flett AS; Gibbs SD; Pinney JH; Maestrini V; Cox AT; Fontana M; Whelan CJ; Wechalekar AD; Hawkins PN; Moon JC
    Circ Cardiovasc Imaging; 2013 Jan; 6(1):34-9. PubMed ID: 23192846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regional amyloid distribution and impact on mortality in light-chain amyloidosis: a T1 mapping cardiac magnetic resonance study.
    Wan K; Li W; Sun J; Xu Y; Wang J; Liu H; Dong Y; Cheng W; Zhang Q; Zeng Z; Zhou X; Han Y; Chen Y
    Amyloid; 2019 Mar; 26(1):45-51. PubMed ID: 30931628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring systemic amyloidosis using MRI measurements of the extracellular volume fraction.
    Campbell-Washburn AE; Price AN; Ellmerich S; Simons JP; Al-Shawi R; Kalber TL; Ghatrora R; Hawkins PN; Moon JC; Ordidge RJ; Pepys MB; Lythgoe MF
    Amyloid; 2013 Jun; 20(2):93-8. PubMed ID: 23621497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measurement of myocardial amyloid deposition in systemic amyloidosis: insights from cardiovascular magnetic resonance imaging.
    Barison A; Aquaro GD; Pugliese NR; Cappelli F; Chiappino S; Vergaro G; Mirizzi G; Todiere G; Passino C; Masci PG; Perfetto F; Emdin M
    J Intern Med; 2015 May; 277(5):605-14. PubMed ID: 25346163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Equilibrium contrast-enhanced CT imaging to evaluate hepatic fibrosis: initial validation by comparison with histopathologic sampling.
    Bandula S; Punwani S; Rosenberg WM; Jalan R; Hall AR; Dhillon A; Moon JC; Taylor SA
    Radiology; 2015 Apr; 275(1):136-43. PubMed ID: 25490188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T1 mapping and survival in systemic light-chain amyloidosis.
    Banypersad SM; Fontana M; Maestrini V; Sado DM; Captur G; Petrie A; Piechnik SK; Whelan CJ; Herrey AS; Gillmore JD; Lachmann HJ; Wechalekar AD; Hawkins PN; Moon JC
    Eur Heart J; 2015 Jan; 36(4):244-51. PubMed ID: 25411195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extracellular volume with bolus-only technique in amyloidosis patients: Diagnostic accuracy, correlation with other clinical cardiac measures, and ability to track changes in amyloid load over time.
    Zumbo G; Barton SV; Thompson D; Sun M; Abdel-Gadir A; Treibel TA; Knight D; Martinez-Naharro A; Thirusha L; Gillmore JD; Moon JC; Hawkins PN; Fontana M
    J Magn Reson Imaging; 2018 Jun; 47(6):1677-1684. PubMed ID: 29159946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myocardial Extracellular Volume Fraction with Dual-Energy Equilibrium Contrast-enhanced Cardiac CT in Nonischemic Cardiomyopathy: A Prospective Comparison with Cardiac MR Imaging.
    Lee HJ; Im DJ; Youn JC; Chang S; Suh YJ; Hong YJ; Kim YJ; Hur J; Choi BW
    Radiology; 2016 Jul; 280(1):49-57. PubMed ID: 27322972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CT findings in hepatic and splenic amyloidosis.
    Suzuki S; Takizawa K; Nakajima Y; Katayama M; Sagawa F
    J Comput Assist Tomogr; 1986; 10(2):332-4. PubMed ID: 3950165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiorgan involvement by amyloid light chain amyloidosis.
    Li G; Han D; Wei S; Wang H; Chen L
    J Int Med Res; 2019 Apr; 47(4):1778-1786. PubMed ID: 30803274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential Myocyte Responses in Patients with Cardiac Transthyretin Amyloidosis and Light-Chain Amyloidosis: A Cardiac MR Imaging Study.
    Fontana M; Banypersad SM; Treibel TA; Abdel-Gadir A; Maestrini V; Lane T; Gilbertson JA; Hutt DF; Lachmann HJ; Whelan CJ; Wechalekar AD; Herrey AS; Gillmore JD; Hawkins PN; Moon JC
    Radiology; 2015 Nov; 277(2):388-97. PubMed ID: 25997029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The liver in systemic amyloidosis: insights from 123I serum amyloid P component scintigraphy in 484 patients.
    Lovat LB; Persey MR; Madhoo S; Pepys MB; Hawkins PN
    Gut; 1998 May; 42(5):727-34. PubMed ID: 9659172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic performance and prognostic value of extravascular retention of 123I-labeled serum amyloid P component in systemic amyloidosis.
    Hazenberg BP; van Rijswijk MH; Lub-de Hooge MN; Vellenga E; Haagsma EB; Posthumus MD; Jager PL
    J Nucl Med; 2007 Jun; 48(6):865-72. PubMed ID: 17504868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component.
    Richards DB; Cookson LM; Berges AC; Barton SV; Lane T; Ritter JM; Fontana M; Moon JC; Pinzani M; Gillmore JD; Hawkins PN; Pepys MB
    N Engl J Med; 2015 Sep; 373(12):1106-14. PubMed ID: 26176329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of 18F-FDG PET(/CT) in patients with systemic and localized amyloidosis.
    Glaudemans AW; Slart RH; Noordzij W; Dierckx RA; Hazenberg BP
    Eur J Nucl Med Mol Imaging; 2013 Jul; 40(7):1095-101. PubMed ID: 23474745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extracardiac
    Wagner T; Page J; Burniston M; Skillen A; Ross JC; Manwani R; McCool D; Hawkins PN; Wechalekar AD
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1129-1138. PubMed ID: 29651545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.